Chemomab Therapeutics Ltd DRC Asset Resilience Ratio
Chemomab Therapeutics Ltd DRC asset resilience ratio. Chemomab Therapeutics Ltd DRC (CMMB) has an Asset Resilience Ratio of 6.72% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Chemomab Therapeutics Ltd DRC defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Chemomab Therapeutics Ltd DRC (2015–2025)
Asset resilience ratio of Chemomab Therapeutics Ltd DRC from 2015 to 2025. This chart shows how Chemomab Therapeutics Ltd DRC's Asset Resilience Ratio has changed over time. Read how much debt does Chemomab Therapeutics Ltd DRC carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Chemomab Therapeutics Ltd DRC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Chemomab Therapeutics Ltd DRC balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $688.00K | 6.72% |
| Total Liquid Assets | $688.00K | 6.72% |
Asset Resilience Insights
- Limited Liquidity: Chemomab Therapeutics Ltd DRC maintains only 6.72% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Chemomab Therapeutics Ltd DRC Industry Peers by Asset Resilience Ratio
Compare Chemomab Therapeutics Ltd DRC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Chemomab Therapeutics Ltd DRC Asset Resilience Ratio by Year (2015–2025)
Chemomab Therapeutics Ltd DRC asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for Chemomab Therapeutics Ltd DRC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 20.29% | $2.80 Million | $13.81 Million | -28.02pp |
| 2024-12-31 | 48.31% | $8.20 Million | $16.96 Million | +0.94pp |
| 2023-12-31 | 47.37% | $10.49 Million | $22.15 Million | -13.88pp |
| 2022-12-31 | 61.25% | $26.37 Million | $43.06 Million | -10.20pp |
| 2021-12-31 | 71.44% | $45.98 Million | $64.35 Million | +71.25pp |
| 2020-12-31 | 0.19% | $24.00K | $12.48 Million | -4.11pp |
| 2015-12-31 | 4.30% | $151.12K | $3.52 Million | -- |
About Chemomab Therapeutics Ltd DRC
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical tri… Read more